Delhi High Court Grants Quia Timet Injunction Barring Intas from Launching Novartis-Patented Dabrafenib
核心洞察
The Delhi High Court granted an ex-parte ad-interim injunction restraining Intas Pharmaceuticals from launching generic Dabrafenib based on Novartis's patent IN'655, valid until 2029.
The court relied on an RTI reply from Gujarat's drug regulator and a private investigation report showing Intas had obtained manufacturing approval and was preparing exhibit batches.
In a separate ruling, the same court barred Torrent Pharmaceuticals from launching Dabrafenib products after Torrent gave an undertaking not to manufacture until patent expiry.
The Delhi High Court has granted an ex-parte ad-interim injunction restraining Intas Pharmaceuticals Limited from commercially launching generic versions of Novartis AG's patented cancer drug Dabrafenib, in a significant application of quia timet patent law that allows pre-emptive relief before actual infringement occurs. In a parallel proceeding, the same court also barred Torrent Pharmaceuticals Ltd. (搜索) from manufacturing or launching any Dabrafenib-containing products after Torrent submitted an undertaking to refrain from doing so until the patent's expiry.
The rulings underscore the Indian judiciary's willingness to act on regulatory paper trails and investigative evidence to prevent imminent patent infringement, rather than waiting for a product to reach pharmacy shelves.
The Dabrafenib Patent and Its Clinical Significance
Dabrafenib is a kinase inhibitor developed to target BRAF (搜索) V600E and V600K gene mutations that drive metastatic melanoma (搜索) and related cancers. The drug works by blocking the activity of the mutated BRAF protein, which otherwise triggers the Mitogen-Activated Protein Kinase (MAPK) or Extracellular Signal-Regulated Kinase (ERK) signaling pathway, leading to persistent and uncontrolled cell proliferation that drives cancer development.
Indian Patent No. 275655 (IN'655), which protects the compound Dabrafenib and pharmaceutical compositions containing it — including its mesylate salt — was originally filed by GlaxoSmithKline LLC and subsequently assigned to Glaxo Group Ltd. before being transferred to Novartis AG in 2016. The patent remains in force in approximately 70 countries and will expire in India on May 4, 2029. Novartis markets the drug in India under the brand name RAFINLAR and internationally as TAFINLAR.
The Intas Case: Quia Timet Relief Based on Regulatory Evidence
In CS(COMM) 433/2026, Novartis AG and its Indian affiliate approached the Delhi High Court seeking to block a patent infringement that had not yet occurred. The suit rested on a reply obtained under the Right to Information Act, 2005 from the Food and Drugs Control Administration (FDCA), Gujarat, which confirmed that Intas had secured manufacturing approval for Dabrafenib active pharmaceutical ingredient (API) and tablets.
A private investigation report by Strategic Analysis India Pvt. Ltd. further corroborated that Intas had developed the API in-house at its Matoda, Gujarat facility, was preparing exhibit batches in 50 mg and 75 mg dosage strengths, and intended to launch commercially in both domestic and export markets, including the US, EU, and Asia.
The court, in its analysis, observed that "the RTI reply from the Food and Drugs Control Administration, Gujarat, when read together with the investigation report, went beyond speculation about Intas's plans." The court noted that manufacturing approval for Dabrafenib API and tablets, combined with evidence of in-house development and exhibit-batch production in two dosage strengths, "painted a coherent picture of an imminent commercial launch rather than an abstract possibility."
Justice Jyoti Singh held that a quia timet action in patent law permits a patentee to seek injunctive relief before actual infringement occurs, provided the apprehension is real and not fanciful. The court distinguished the present claim from one built on rumor or generic market comparison, and further observed that favorable orders Novartis had obtained in earlier, comparable enforcement suits reinforced the credibility of its apprehension.
On the question of pre-institution mediation under Section 12A of the Commercial Courts Act, 2015, the court relied on the Supreme Court's reasoning in Yamini Manohar v. T.K.D. Keerthi, opining that the provision does not apply where a suit genuinely contemplates urgent interim relief. Since patent infringement, once materialized, is continuing in nature and causes recurring harm to a patentee's exclusivity, pre-institution mediation was properly dispensed with.
The court found that the certificate of grant for Patent IN'655, its subsisting term until 2029, and Novartis's substantial and growing RAFINLAR sales established a strong prima facie case. The balance of convenience favored Novartis given the imminent risk of a competing product entering the market, and the resulting loss of market share, goodwill, and pricing power would be difficult to compensate through damages alone.
The ex-parte ad-interim injunction restrains Intas from manufacturing, using, stockpiling, importing, selling, offering for sale, distributing, or exporting API or formulations containing Dabrafenib, including its mesylate salt. Intas was granted liberty to file a reply within four weeks, with the interim order remaining open to reconsideration once the company is heard on merits.
The Torrent Pharmaceuticals Parallel Proceeding
In a separate but related matter, Novartis AG and Novartis India Ltd. had moved the court seeking a decree of permanent injunction against Torrent Pharmaceuticals. When the case came up for hearing, Torrent's counsel submitted an undertaking that the company would not manufacture or launch any product containing Novartis's patented compound during the validity of the patent.
The petitioners stated that their suit could be disposed of noting Torrent's undertaking, and they would not press monetary relief against the respondent. The high court decreed the suit in favor of Novartis, with Justice Jyoti Singh stating: "The suit is accordingly decreed in terms of the undertaking given by the defendant, which shall form a part of the decree and disposed of along with pending applications."
Preservation of the Bolar Exemption
In both rulings, the Delhi High Court expressly preserved the defendants' rights under Section 107A of the Patents Act, 1970 — India's regulatory or "Bolar" exemption — which permits acts reasonably related to the development and submission of information for regulatory approval. In the Intas matter, the court noted that Intas's rights under Section 107A, "insofar as reasonably related to development and regulatory submissions, were expressly protected notwithstanding the injunction." Similarly, in the Torrent matter, the court stated that Torrent's rights under Section 107A "to use Dabrafenib for the purpose of research, be protected, subject to compliance of this provision."
These rulings illustrate how regulatory transparency filings can become potent evidence in pre-emptive patent litigation, and how Indian courts balance urgency against the mandatory mediation requirements of commercial litigation while preserving statutory research exemptions for generic manufacturers.